asxan.ai Agents Hub

Probiotics

Evidence Fact Sheet

live beneficial microorganisms

Probiotics are live beneficial microorganisms (e.g. Lactobacillus, Bifidobacterium, Saccharomyces boulardii) studied for gut and immune support via microbiota modulation and gut-barrier effects. Trials commonly use 1-50 billion CFU/day; effects are strain- and indication-specific. Sold as supplements under DSHEA/2002/46/EC; no generic FDA/EFSA health claim for "probiotics."

Also known as: Probiotic · Live cultures · Lactobacillus / Bifidobacterium spp. · Saccharomyces boulardii · Beneficial gut bacteria

Overview

Probiotics are live beneficial microorganisms — most commonly Lactobacillus and Bifidobacterium species plus the yeast Saccharomyces boulardii — proposed to act by competitive exclusion of pathogens, modulation of gut microbiota composition, strengthening of the intestinal epithelial barrier, production of short-chain fatty acids, and immune modulation via gut-associated lymphoid tissue (all research-context mechanisms). Research doses commonly fall in the range of 1-50 billion CFU/day, but effects are strain- and indication-specific, so there is no single "probiotic" dose and evidence for one strain does not transfer to another. In the US, many strains hold self-affirmed or notified GRAS status and are sold as dietary supplements under DSHEA with structure/function claims only; there is no generic FDA-authorized health claim for "probiotics." In the EU, the only authorized Reg 432/2012 claim covers live yogurt cultures (L. delbrueckii subsp. bulgaricus + S. thermophilus) for lactose digestion at >=10^8 CFU/g, and the generic term "probiotic" is treated as an unauthorized claim; ANVISA (Brazil) and China permit only listed/approved strains. This is an educational evidence summary, not medical advice or a treatment for any disease.

Mechanism of Action

Competitive exclusion of pathogens and modulation of gut microbiota composition (research context) · Strengthening of intestinal epithelial barrier and tight-junction function (mechanistic) · Production of short-chain fatty acids (SCFAs · e.g. butyrate) from fermentation (research context) · Immune modulation via gut-associated lymphoid tissue and cytokine signaling (research context) · Lactase activity of live yogurt cultures aiding lactose digestion (EFSA-authorized mechanism for L. bulgaricus + S. thermophilus)

Body systems: Digestive & Gut · Immune System

Evidence-Based Benefits

Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Probiotics is not characterized as a treatment for any disease.

Antibiotic-Associated Diarrhea (Prevention)

Meta-analysis supported
  • RR 0.5895% CI 0.50-0.68 · p<.001
  • 63 RCTs11,811 participants
  • NNT 1395% CI 10.3-19.1

In a large meta-analysis of 63 randomized controlled trials, probiotic administration was associated with a statistically significant reduction in antibiotic-associated diarrhea compared with control, with a number needed to treat of about 13. This is among the strongest and most consistent probiotic findings, though benefit is strain- and population-specific.

Reported effect: relative risk 0.58; 95% CI, 0.50 to 0.68; P < .001 across 63 RCTs and 11,811 participants; NNT 13

“The pooled relative risk in a DerSimonian-Laird random-effects meta-analysis of 63 RCTs, which included 11 811 participants, indicated a statistically significant association of probiotic administration with reduction in AAD (relative risk, 0.58; 95% CI, 0.50 to 0.68; P < .001”

Source: PMID 22570464 · Hempel 2012 · JAMA

Clostridium Difficile-Associated Diarrhea (Prevention)

Meta-analysis supported
  • RR 0.4095% CI 0.30-0.52 · CDAD
  • 31 trials8,672 participants
  • 1.5% vs 4.0%probiotic vs control

A Cochrane review of 31 trials found a lower incidence of Clostridium difficile-associated diarrhea (CDAD) in the probiotic group (1.5%) than in the placebo/no-treatment control group (4.0%), graded as moderate-certainty evidence. Effect was larger in higher-baseline-risk populations.

Reported effect: CDAD incidence 1.5% (70/4525) probiotic vs 4.0% (164/4147) control; RR 0.40, 95% CI 0.30 to 0.52; 31 trials, 8,672 participants

“The incidence of CDAD was 1.5% (70/4525) in the probiotic group compared to 4.0% (164/4147) in the placebo or no treatment control group (RR 0.40, 95% CI 0.30 to 0.52; GRADE = moderate).”

Source: PMID 29257353 · Goldenberg 2017 · Cochrane Database Syst Rev

Irritable Bowel Syndrome (Symptoms)

Meta-analysis supported
  • MD -1.66abdominal pain · 95% CI -2.39 to -0.93
  • MD -2.13bloating · 95% CI -3.96 to -0.30
  • 23 studies3,288 participants

A systematic review and meta-analysis of 23 studies in irritable bowel syndrome reported that probiotics significantly reduced abdominal pain and bloating versus comparator. Authors of this literature note results vary by strain and population, so the pooled effect should not be generalized to any single product.

Reported effect: abdominal pain mean difference -1.66 (95% CI -2.39 to -0.93, p<0.0001); bloating MD -2.13 (95% CI -3.96 to -0.30, p=0.0224); 23 studies, 3,288 participants

“Probiotics significantly reduced abdominal pain (mean difference = -1.66, 95% CI = -2.39 to -0.93, p < 0.0001) and bloating (mean difference = -2.13, 95% CI = -3.96 to -0.30, p = 0.0224).”

Source: PMID 39830577 · Almabruk 2024 · Cureus

Acute Upper Respiratory Tract Infections (Prevention)

Meta-analysis supported
  • OR 0.53>=1 URTI episode · 95% CI 0.37-0.76
  • 12 trials3,720 participants

A Cochrane review found probiotics were better than placebo at reducing the number of participants experiencing at least one acute upper respiratory tract infection episode. The authors graded the evidence as low quality, so the finding is suggestive rather than definitive.

Reported effect: at least one URTI episode: odds ratio 0.53; 95% CI 0.37 to 0.76; 12 trials, 3,720 participants; low-quality evidence

“probiotics were better than placebo when measuring the number of participants experiencing episodes of acute URTI (at least one episode: odds ratio (OR) 0.53; 95% confidence interval (CI) 0.37 to 0.76”

Source: PMID 25927096 · Hao 2015 · Cochrane Database Syst Rev

Acute Infectious Diarrhea — Duration (Honest Negative)

Null / no benefit Meta-analysis supported
  • MD 8.64 h shorter95% CI 29.4 shorter to 12.1 longer
  • 6 trials3,058 participants
  • very low certaintyGRADE quality

An updated Cochrane review found probiotics probably make little or no difference to whether diarrhea lasts 48 hours or longer, and that the effect on mean duration was uncertain (confidence interval crossing no effect). This 2020 update overturned earlier reviews that had suggested a benefit, after adding large well-conducted trials and accounting for publication bias.

Reported effect: mean duration of diarrhoea MD 8.64 hours shorter (95% CI 29.4 hours shorter to 12.1 hours longer); 6 trials, 3,058 participants; very low-certainty evidence

“we are uncertain whether probiotics reduce the duration of diarrhoea" (MD 8.64 hours shorter, 95% CI 29.4 hours shorter to 12.1 hours longer; 6 trials, 3058 participants; very low-certainty evidence).”

Source: PMID 33295643 · Collinson 2020 · Cochrane Database Syst Rev

Dosage (research context · not a recommendation)

Educational reference, not a dosing recommendation. Trials commonly use 1-50 billion CFU/day; effects are strain- and indication-specific (no single 'probiotic' dose). The EFSA-authorized live-yogurt-culture lactose claim requires >=10^8 CFU/g of L. delbrueckii subsp. bulgaricus + S. thermophilus.

Regulatory Status · 4 Markets

US · FDA
Many probiotic strains hold self-affirmed or notified GRAS status and are lawfully sold as dietary supplements under DSHEA; structure/function claims only with mandatory disclaimer. NO generic FDA-authorized health claim for 'probiotics' (the 2026 yogurt qualified health claim is product/strain-specific). 'FDA approved' is prohibited.
EU · EFSA
One EFSA-authorized Reg 432/2012 claim covers live yogurt cultures (L. delbrueckii subsp. bulgaricus + S. thermophilus) improving lactose digestion at >=10^8 CFU/g. The generic term 'probiotic' is treated as an unauthorized health claim in the EU; supplements are otherwise lawful under Directive 2002/46/EC.
CN · China
Permitted: China maintains an NHC positive list of probiotic strains (~39) usable in common food; listed strains are lawful in food, and probiotic health foods can be registered with SAMR (Blue Hat). Strain must be on the approved inventory.
BR · ANVISA
Probiotic strains are permitted in dietary supplements (suplementos alimentares) under the ANVISA RDC 243/2018 framework and probiotics technical regulation, subject to the approved strain list and viability requirements; no generic IN 28/2018 Anexo V functional claim for the 'probiotics' category.

Safety

Generally well tolerated in healthy adults; transient bloating/gas may occur at start. Caution and medical guidance for immunocompromised, critically ill, central-venous-catheter, or short-bowel patients (rare risk of bacteremia/fungemia). Effects are strain-specific — evidence for one strain does not transfer to another. Quality/viability varies by product. No adequate data for some strains in pregnancy/lactation. Educational, not medical advice — not a treatment for any disease.

Goals: gut-digestion · inflammation-relief

Lifestyles: weight-management · senior-60-plus

References

PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.

  1. PMID 22570464 · Hempel 2012 · JAMA — Antibiotic-Associated Diarrhea (Prevention)
  2. PMID 29257353 · Goldenberg 2017 · Cochrane Database Syst Rev — Clostridium Difficile-Associated Diarrhea (Prevention)
  3. PMID 39830577 · Almabruk 2024 · Cureus — Irritable Bowel Syndrome (Symptoms)
  4. PMID 25927096 · Hao 2015 · Cochrane Database Syst Rev — Acute Upper Respiratory Tract Infections (Prevention)
  5. PMID 33295643 · Collinson 2020 · Cochrane Database Syst Rev — Acute Infectious Diarrhea — Duration (Honest Negative)

Frequently Asked Questions

1. What does the evidence actually support for probiotics?

The strongest pooled evidence is for preventing antibiotic-associated diarrhea (Hempel 2012 meta-analysis of 63 RCTs, RR 0.58) and Clostridium difficile-associated diarrhea (Goldenberg 2017 Cochrane review of 31 trials, RR 0.40, moderate certainty). Meta-analyses also report reduced abdominal pain and bloating in irritable bowel syndrome and fewer upper-respiratory-infection episodes, though those are lower-certainty. This is research-finding information, not a treatment recommendation.

2. Are there negative or null findings?

Yes. The 2020 Cochrane review (Collinson) on probiotics for treating acute infectious diarrhea concluded probiotics probably make little or no difference to whether diarrhea lasts 48 hours or longer, and the effect on mean duration was uncertain (MD 8.64 hours shorter, 95% CI ranging from 29.4 hours shorter to 12.1 hours longer). This update overturned earlier reviews that had suggested a benefit, after accounting for large new trials and publication bias.

3. Does evidence for one probiotic apply to all probiotics?

No. Effects are strain-specific, and evidence for one strain does not transfer to another. The pooled meta-analysis numbers above combine different strains, doses, and populations, so they describe a category-level signal rather than the performance of any single product or strain.

4. What dose is used in research, and is it regulated as a drug?

Trials commonly use roughly 1-50 billion CFU/day, but there is no single 'probiotic' dose because effects are strain- and indication-specific. Probiotics are sold as dietary supplements (DSHEA in the US, 2002/46/EC in the EU) with structure/function claims only; there is no generic FDA- or EFSA-authorized health claim for 'probiotics' (the only EU-authorized claim covers live yogurt cultures for lactose digestion). This page reports research findings and is not clinical or dosing guidance.

Last evidence review: 2026-06-22

← Evidence library

Ask Agent Axor